Skip to content

SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases

Evaluation of SWE as a Predictive Tool for Progression of Chronic Liver Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03389152
Acronym
SWE Predict
Enrollment
2148
Registered
2018-01-03
Start date
2007-07-26
Completion date
2019-11-28
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibroses

Brief summary

This study is a multicenter individual patient-based meta-analysis that will assess the performances of liver stiffness measurements performed with supersonic shear imaging shearwave elastography (SSI-SWE) in patients with liver fibrosis to predict progression of chronic liver disease.

Interventions

DEVICEElastography

liver stiffness measurements by shear wave-based elastography

Sponsors

University of Bonn
CollaboratorOTHER
SuperSonic Imagine
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who had received a liver ultrasound exam at baseline for a suspected chronic fibrotic liver disease of viral and/or steatotic origin, * Patients who had reached the age of majority in their countries, at baseline, * Patients with a baseline liver biopsy for histological evaluation of liver fibrosis with a length ≥ 15 mm paraffin sections (except if cirrhosis), * Patients for whom a minimum length of clinical follow-up from baseline of 1 year had been recorded

Exclusion criteria

* Cause of chronic liver disease other than viral, ALD or NAFLD ( hemochromatosis, autoimmune hepatitis, biliary tract disease intrahepatic...) * Any systemic, viral hepatitis and HIV co-infection

Design outcomes

Primary

MeasureTime frameDescription
Liver disease progression rateMinimum of 28 days follow-upClinical signs of liver decompensation
Mortality rateMinimum of 28 days follow-upPatient's death

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026